Recurrent bronchitis immunomodulation in children with vertebrobasilar arterial system syndrome
DOI:
https://doi.org/10.34287/MMT.4(47).2020.9Abstract
Purpose of the study. To increase of recurrent bronchitis (RB) immunoprophylaxis effectiveness inchildrenaged 7 to 12 yearswiththevertebrobasilar arterial system syndrome (VBASS).
Materials and methods. 60 children aged 7 to 12 years with RB and VBASS were examined. Two groups were formed (30 children each): 1) children with RB and VBASS receiving ω-3 polyunsaturated fatty acids (PUFA) at 300 mg per day during meals for 60 days; 2) children with RB and VBASS receiving multivitamins in a prophylactic daily dose during meals for 60 days. The state of immunity was assessed by data on phagocytosis, CD3, CD4, CD8, CD16, CD19, CD25, CD95; serum levels of IgA, IgG, IgM, tumor necrosis factor-α (TNF-α) and secretory sIgA in saliva.
Results. When ω-3 PUFA is used, the frequency of registration of low indices of phagocytic index decreases (by 16,7%, p < 0,05), phagocytic number (by 28,4%, p < 0,05), index of phagocytosis completion (by 15,0%, p < 0,05), the spontaneous NST-test index (by 10,0%, p < 0,05), the CD16 content (by 10,0%, p < 0,05); the number of children decreases with an increase in CD3 (by 21,7%, p < 0,05), CD8 (by 15,0%, p < 0,05), CD19 (by 16,7%, p < 0,05), CD25 (by 31,6%, p < 0,05), CD95 (by 18,4%, p < 0,05), serum IgG (by 11,7%, p < 0,05), IgM (by 31,7%, p < 0,05), TNF-α (by 30,0%, p < 0,05) and decreased IgA level (by 15,0%, p<0,05), saliva sIgA (by 31,6%, p < 0,05).
Conclusions. The use of ω-3 PUFA is an effective remedy for RB immunoprophylaxis in children with (на 11,7%, р < 0,05), IgМ (на 31,7%, р < 0,05), ФНО-α (на 30,0%, р < 0,05) и сниженного уровня IgА (на 15,0%, р < 0,05), sIgA слюны (на 31,6%, р < 0,05).
VBASS, which is associated with the universal regulatory mechanism of immunotropic influence – protective and anti-inflammatory.
References
Brenna J.T., Salem Jr N., Sinclair A.J., Cunnane S.C. Alpha-linolenic acid supplementation and conversion to n-3 long-chain polyunsaturated fatty acids in humans. Prostaglandins Leukot. Essent. Fat Acids. 2009; 80: 85–91.
Lee H.-S., Barraza-Villarreal A., HernandezVargas H. et al. Modulation of DNA methylation states and infant immune system by dietary supplementation with ω-3 PUFA during pregnancy in an intervention study. Am. J. Clin. Nutr. 2013; 98 (2): 480–487.
Birch E.E., Khoury J.C., Berseth C.L. et al. The impact of early nutrition on incidence of allergic manifestations and common respiratory illnesses in children. J. Pediatr. 2010; 156 (6): 902–906.
Thienprasert A., Samuhaseneetoo S., Popplestone K. et al. Fish oil n-3 polyunsaturated fatty acids selectively affect plasma cytokines and decrease illness in Thai schoolchildren: a randomized double-blind, placebo-controlled intervention trial. J. Pediatr. 2009; 154: 391–395.
Pastor N., Soler B., Mitmesser S.H. et al. Infants fed docosahexaenoic acidand arachidonic acid-supplemented formula have decreased incidence of bronchiolitis/bronchitis the first year of life. Clin. Pediatr. (Phila). 2006; 45 (9): 850–855.
Carlo T. Levy B.D. Molecular Circuits of Resolution in Airway Inflammation. ScientificWorldJournal. 2010; 10: 1386–1399.
Minns L.M., Kerling E.H., Neely M.R. et al. Toddler formula supplemented with docosahexaenoic acid (DHA) improves DHA status and respiratory health in a randomized, doubleblind, controlled trial of US children less than 3 years of age. Prostaglandins Leukot. Essent. Fat Acids. 2010; 82: 287–293.
Siniscalchi A., Sztajzel R., Malferrari G., Gallelli L. The National Institutes of Health Stroke Scale: Its Role in Patients with Posterior Circulation Stroke. Hospital Topics. 2017; (2): 1–3.
